Budget Impact of Subcutaneous Immunoglobulin, Intravenous Immunoglobulin, and Efgartigimod Alfa in Patients With Chronic Inflammatory Demyelinating Polyneuropathy in the United States

Mallick R, CSL Behring, King of Prussia, PA, USA; Carlton R, Cencora, Bern, Switzerland, PA; Lahue B, Alkemi, Manchester Center, VT, USA

Introduction

- Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, progressive autoimmune disease causing peripheral nervous system dysfunction.¹
- Subcutaneous immunoglobulin (SCIG) or intravenous immunoglobulin (IVIG) therapy are recommended as first line immunomodulatory agent in CIDP.
- Efgartigimod alfa, a novel FcRn antagonist, is expected to become available as an additional option for CIDP patients.

Objective

 To estimate the budget impact of efgartigimod alfa in a proportion of CIDP patients currently receiving SCIG and IVIG.

Methods

- A budget impact model was developed to project, from a US integrated delivery network perspective, the costs expected with efgartigimod alfa for CIDP maintenance therapy, in relation to the current standard of care consisting of IVIG and SCIG (IgPro20) treatment.
- Cost inputs included drug acquisition (pharmacy) costs, administration costs by site of care, infusionrelated complications, systemic side effects, and indirect costs.²⁻⁶
- Pharmacy costs were based on a payment mix of average sales price (ASP) (73%), wholesale acquisition cost (WAC) (2%), and average wholesale price (AWP) (25%).7
- The PATH clinical study of IgPro20 (Hizentra) maintenance was the basis for input on relapse rates at initial assessment (24 weeks) and at 52 weeks for each of its 2 doses – high dose (0.4 g/kg/bodyweight (bw) and low dose (0.2 g/kg/bw).^{8,9}
- The ICE clinical study of IVIG maintenance therapy was the basis for input on relapse rates for IVIGs
- The recent ADHERE clinical study was used to obtain relapse rates of efgartigimod.^{10,11}

Table 1. Pharmacy costs							
	Hizentra	IVIG	Vyvgart Hytrulo				
Reimbursed Average Sales Price (ASP)	\$12.73 (100 mg)	\$48.35 (500 mg)	\$16,050.00 (1 g)				
Wholesale Acquisition Cost (WAC)	\$227.42 (1 g)	\$165.94 (1 g)	\$16,586.69 (1 g)				
Average Wholesale Price (AWP)	\$211.12 (1 g)	\$154.04 (1 g)	\$15,397.45 (1 g)				
Average Price per Gram	\$150.24	\$112.42	\$15,897.60				

Presented at ISPOR 2024 | May 5-8, 2024 | Atlanta, GA

treatment, an expected 708 CIDP patients treated with IG.






Table 2. Total cost increase, assuming assuming a 10% uptake of efgartigimod alfa in year 1, drawing patient share proportionally from IVIG and SCIG						
	Current	Year 1	Budget Im- pact	Per- centage Change		
Drug costs	\$106,636,966	\$154,714,897	\$48,077,931	45.1%		
Non-drug costs	\$22,791,732	\$20,712,281	-\$2,079,450	-9.1%		
Total costs	\$129,447,314	\$175,444,022	\$45,996,708	35.5%		






Mallick R and Hubsch A are employees of CSL Behring; Carlton R and van Stiphout are employees of Cencora; Lahue B is an employee of Alkemi This study was funded by CSL Behring

Results cont.

 Assuming a 10% uptake of efgartigimod alfa in year 1 (drawing patient share exclusively from IVIG) led to a projected total budget impact of \$46,079,091, a 35.6% increase.

e 3. Total cost increase, assuming a 10% uptake fgartigimod alfa in year 1 drawing patient share usively from IVIG								
	Current	Year 1	Budget impact	Per- centage change				
ug sts	\$106,636,966	\$154,938,938	\$48,301,972	45.3%				
drug sts	\$22,791,732	\$20,568,851	-\$2,222,881	-9.8%				
al ts	\$129,447,314	\$175,526,406	\$46,079,091	35.6%				

Figure 3. Budget impact assuming a 10% uptake of efgartigimod alfa in year 1 drawing patient share exclusively from IVIG



Conclusion

This analysis suggests that efgartigimod alfa is expected to result in substantially increased spending in treatment of CIDP. This conclusion follows from: Substantially higher publicly known price of efgartigimod alfa, as translated via dose adjustment from myasthenia gravis pricing to CIDP pricing. The absence of a documented relapse management approach with efgartigimod alfa, as opposed to known relapse management outcomes documented in the PATH open-label extension study, and incorporating the cost of untreated relapses.

References

- 1. Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019;18(8):784-794. 2. Red Book Online. IBM Micromedex. Copyright IBM Corporation 2023. Accessed November 8, 2023. 3. Centers for Medicare and Medicaid Services (CMS). Effective October 1, 2023 through December 31, 2023 Pricing
- File. Accessed November 8, 2023. https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2022asp-drug-pricing-files 4. Centers for Medicare and Medicaid Services (CMS). Hospital Outpatient Prospective Patient System (OPPS).
- Accessed November 8, 2023. https://www.cms.gov/license/ama?file=/files/zip/october-2023-opps-addendum-b.zip 5. Slen B. Infused therapies: cost savings benefits through home infusion. Specialty Pharmacy Times. 2014;5(1):24-25. 6. Centers for Medicare and Medicaid Services (CMS). Physician Fee Schedule Search. Page last modified: September 6, 2023. Accessed November 8, 2023. https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx 7. AMCP. AMCP Pharmaceutical Payment Methods, 2013 Update. 2013. Accessed November 28, 2022. https://www. amcp.org/guide-pharmaceutical-payment-methods
- 8. Van Schaik I, Bril V, van Geloven et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17:35-46
- 9. Van Schaik I, Meilke O, Bril V, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro 20 in CIDP. Neurol Neuroimmunol Neuroinflamm. 2019;6(5):e590. 10.Hughes R, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the
- treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebocontrolled trial. Lancet Neurol. 2008;7: 136-144. 11. argenx press release. argenx reports positive topline data from ADHERE study of Vyvgart Hytrulo in patients with
- chronic inflammatory demyelinating polyneuropathy. July 17, 2023. https://www.us.argenx.com/sites/default/files/ media-documents/Press-Release_ARGX_ADHERE_Data_Release.pdf

Disclosures